Rituximab with GMALL-B-ALL-BFM
Treatment for Burkitt lymphoma
Typical Dosage: Complex multi-drug, multi-phase inpatient regimen, intravenously
Effectiveness
90%
Safety Score
25%
Clinical Trials
35
Participants
3.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Complex multi-drug, multi-phase inpatient regimen, intravenously
Time to Effect
Within weeks of starting cycles
Treatment Duration
4-6 months (multiple blocks)
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$130,000
Monitoring:$90,000
Side Effect Mgmt:$55,000
Total Annual:$275,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$45,833/QALY
QALYs Gained
6
Outcome-Based Costs
Cost per Responder
$305,555.56
Cost per Remission
$323,529.41
Rituximab with GMALL-B-ALL-BFM Outcomes
for Burkitt lymphoma
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Remission Rate
+85%
Common Side Effects
Myelosuppression (Neutropenia, Thrombocytopenia, Anemia)
+95%
Febrile Neutropenia/Infection
+60%
Mucositis/Stomatitis
+70%
Nausea/Vomiting
+85%
Fatigue
+80%
Alopecia
+90%
Neurotoxicity (Vincristine-induced)
+30%
Cardiotoxicity (Doxorubicin-induced)
+8%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov